ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,823 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentMuttenzPerseo pharma AG
Perseo pharma AG Logo
Verified· 3 sources

Perseo pharma AG

Summary

About the company

The core activity of Perseo Pharma AG is the development of enzyme replacement therapies for the treatment of metabolic diseases, in particular for rare diseases such as exocrine pancreatic insufficiency, congenital sucrase-isomaltase deficiency and maple syrup urine disease. The company develops innovative therapies based on the enzzen platform technology and focuses on the clinical development of active ingredients for the treatment of these diseases.

AI-generated
Offering

Products & services

Industry:Research & Development
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
Pharmaceutical Industry
✓ Offered5
Development of Enzyme Therapeutics
Development of oral enzyme therapies for digestive conditions, based on a proprietary nanotechnology platform with nano-shield and muco-adhesive coating.
Nanotechnology Platform for Oral Enzyme Therapies
Proprietary platform that protects enzymes in silica nanoparticles and an organo-silica layer, prolonging their residence time in the small intestine and maintaining activity.
Development of Therapies for Digestive Diseases
Research and development of therapies for exocrine pancreatic insufficiency, carbohydrate malabsorption, PKU, CSID and MSUD.
Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases
Research on systemic enzyme replacement therapies for lysosomal storage diseases as part of the second development wave.
Partnerships for the Co-Development of Innovative Therapies
Cooperations for the co-development of innovative therapies in the areas of metabolic therapies, onco-metabolism and systemic enzyme replacement therapies.
Press

Media

May 15, 2019Media
INOFEA spins-off Perseo Pharma to further develop therapeutic enzymes
startupticker.ch
Comparisons

Perseo pharma AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Perseo pharma AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Perseo pharma AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hofackerstrasse 40B
4132 Muttenz

At a glance

Legal form
Corporation
UID
CHE-492.603.214
Founded
2019 · 7 years
Last commercial register change
October 24, 2025
Employees
11 to 20

Knowledge

No knowledge articles yet

Once Perseo pharma AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started

Similar companies

IA
INOFEA AG
Muttenz
PC
Preclin Consulting GmbH
Muttenz
IA
InCephalo AG
Allschwil
AP
Actelion Pharmaceuticals Ltd
Allschwil
SF
Stiftung Forschung Klinik Arlesheim
Arlesheim
BP
Bright Peak Therapeutics AG
Allschwil
MH
Monix Health AG
Allschwil
DA
DeltaMem AG
Allschwil